Ra Medical Systems Stock Forecast, Price & News

+0.01 (+0.19 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume975,933 shs
Average Volume3.04 million shs
Market Capitalization$17.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Medical Systems and its competitors with MarketBeat's FREE daily newsletter.

Ra Medical Systems logo

About Ra Medical Systems

Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.15 out of 5 stars

Medical Sector

1020th out of 2,100 stocks

Surgical & Medical Instruments Industry

97th out of 174 stocks

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ra Medical Systems (NYSE:RMED) Frequently Asked Questions

Is Ra Medical Systems a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ra Medical Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMED, but not buy additional shares or sell existing shares.
View analyst ratings for Ra Medical Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Ra Medical Systems?

Wall Street analysts have given Ra Medical Systems a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ra Medical Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ra Medical Systems' next earnings date?

Ra Medical Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Ra Medical Systems

How were Ra Medical Systems' earnings last quarter?

Ra Medical Systems, Inc. (NYSE:RMED) released its quarterly earnings data on Tuesday, May, 11th. The company reported ($2.48) EPS for the quarter, beating analysts' consensus estimates of ($2.94) by $0.46. The business earned $1.12 million during the quarter. Ra Medical Systems had a negative net margin of 857.56% and a negative trailing twelve-month return on equity of 151.70%.
View Ra Medical Systems' earnings history

How has Ra Medical Systems' stock price been impacted by Coronavirus (COVID-19)?

Ra Medical Systems' stock was trading at $31.4075 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RMED stock has decreased by 83.4% and is now trading at $5.22.
View which stocks have been most impacted by COVID-19

When did Ra Medical Systems' stock split? How did Ra Medical Systems' stock split work?

Ra Medical Systems shares reverse split on Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 16th 2020. An investor that had 100 shares of Ra Medical Systems stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for RMED?

2 analysts have issued 1-year target prices for Ra Medical Systems' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Ra Medical Systems' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 34.1% from the stock's current price.
View analysts' price targets for Ra Medical Systems
or view top-rated stocks among Wall Street analysts.

Who are Ra Medical Systems' key executives?

Ra Medical Systems' management team includes the following people:
  • Mr. Jonathan Will McGuire, CEO & Director (Age 58, Pay $799.48k)
  • Mr. Andrew C. Jackson, Chief Financial Officer (Age 52, Pay $711.66k)
  • Mr. Daniel Horwood, Gen. Counsel & Sec. (Age 47, Pay $577.19k)
  • Ms. Tiah Reppas, VP, Chief Accounting Officer & Corp. Controller
  • Ms. Maria Villanueva Sessions, VP & Compliance Officer

Who are some of Ra Medical Systems' key competitors?

What other stocks do shareholders of Ra Medical Systems own?

When did Ra Medical Systems IPO?

(RMED) raised $50 million in an initial public offering on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

What is Ra Medical Systems' stock symbol?

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

Who are Ra Medical Systems' major shareholders?

Ra Medical Systems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Royce & Associates LP (9.75%), Renaissance Technologies LLC (4.78%), Dowling & Yahnke LLC (2.10%), GSA Capital Partners LLP (1.52%), Virtu Financial LLC (0.90%) and Bank of New York Mellon Corp (0.59%). Company insiders that own Ra Medical Systems stock include Dean Irwin, Jonathan Will Mcguire, Martin Burstein, Martin J Colombatto, Richard Mejia Jr and William R Enquist.
View institutional ownership trends for Ra Medical Systems

Which institutional investors are buying Ra Medical Systems stock?

RMED stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Dowling & Yahnke LLC, GSA Capital Partners LLP, Virtu Financial LLC, Bank of New York Mellon Corp, Morgan Stanley, Geode Capital Management LLC, and Renaissance Technologies LLC. Company insiders that have bought Ra Medical Systems stock in the last two years include Jonathan Will Mcguire, Martin J Colombatto, Richard Mejia Jr, and William R Enquist.
View insider buying and selling activity for Ra Medical Systems
or or view top insider-buying stocks.

How do I buy shares of Ra Medical Systems?

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ra Medical Systems' stock price today?

One share of RMED stock can currently be purchased for approximately $5.22.

How much money does Ra Medical Systems make?

Ra Medical Systems has a market capitalization of $17.00 million and generates $4.41 million in revenue each year.

How many employees does Ra Medical Systems have?

Ra Medical Systems employs 86 workers across the globe.

What is Ra Medical Systems' official website?

The official website for Ra Medical Systems is www.ramed.com.

Where are Ra Medical Systems' headquarters?

Ra Medical Systems is headquartered at 2070 Las Palmas Drive, Carlsbad CA, 92011.

How can I contact Ra Medical Systems?

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]

This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.